药物信息为ENBREL (etanercept) For Subcutaneous Injection (Immunex Corp): REFERENCES
- DESCRIPTION
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- OVERDOSAGE
- HOW SUPPLIED
- REFERENCES
- Medication GuideENBREL® (en-brel)(etanercept)
- Patient Instructions for UseENBREL® (en-brel)(etanercept)Single-use Prefilled Syringe
- Patient Instructions for UseENBREL® (en-brel)(etanercept)Multiple-use Vial
- Patient Instructions for UseENBREL® (en-brel)(etanercept)Single-use Prefilled SureClick™ Autoinjector
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - PREFILLED SYRINGE, 25 MG
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - PREFILLED SYRINGE, 50 MG
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - PREFILLED AUTOINJECTOR, 50 MG
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - VIAL, 25 MG
- 外部链接相关的ENBREL (etanercept) For Subcutaneous Injection (Immunex Corp)
- Ramey DR, Fries JF, Singh G. The Health Assessment Questionnaire 1995 - Status and Review. In: Spilker B, ed. “Quality of Life and Pharmacoeconomics in Clinical Trials.” 2nd ed. Philadelphia, PA. Lippincott-Raven 1996;227.
- Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998;51(11):903.
- Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement of juvenile arthritis. Arthritis Rheum 1997;40(7):1202.
- Fredriksson T, Petersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238.
- van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27(4):361-8.
- Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44(8):1876-86.
- Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531.
- Arnason BGW, et al. (Lenercept Multiple Sclerosis Study Group). TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457.
- Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334(26):1697.
- National Cancer Institute. Surveillance, Epidemiology, and End Results Database (SEER) Program. SEER Incidence Crude Rates, 11 Registries, 1992-1999.
- Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid Arthritis and Cancer Risk. Eur J Cancer 1996;32A(10):1753-1757.
- Baecklund E, Ekbom A, Sparen P, et al. Disease Activity and Risk of Lymphoma in Patients With Rheumatoid Arthritis: Nested Case-Control Study. BMJ 1998;317:180-181.
- Drug Information Provided by National Library of Medicine (NLM).
这个站点被设计主要作为提示系统供合格的医师和其他医疗专家使用。 通过使用这个站点您了解并且接受DiagnosisPro.com不会使用作为一个诊断决策系统，并且不能使用做一个临床诊断或替换或者否决一位被准许的医疗保健专家的评断或临床诊断 (充分的使用条款). 我们遵循健康网络基金会的 医学和健康网站的行为准则. 点击这里核实
© 2013 MedTech USA, Inc. (最后更新在05/20/13)
